ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
Healthcare
$10.90 +1.40%
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
52W Low $16.10High $33.62
Volume 2.70M
Average 0.50M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$160.59M
FY 2025 · Annual
Investing Cash Flow
-$71.23M
FY 2025 · Annual
Financing Cash Flow
$203.06M
FY 2025 · Annual
+8.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$166.3M
+ D&A-$3.0M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
- Working Capital-$3.8M
+ Other Non-Cash$0
= Operating Cash Flow-$160.6M
- Capex$0
= Free Cash Flow-$160.6M
Analysis
FY2025 free cash flow is -$160.6M. FCF conversion is 96.6% of net income. Operating cash flow was -$160.6M, with capex of $0. The largest bridge item is Stock-Based Comp at $12.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 8-K | Current report | Oct 26, 2026 |
Does AVBP generate free cash flow?
ArriVent BioPharma, Inc. Common Stock (AVBP) generated -$160.59M of free cash flow in fiscal 2025.
How much operating cash flow does AVBP produce?
Operating cash flow was -$160.59M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.